<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>498-INDIRECT-SYMPATHOMIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG1>
<DRUG2>
<CLASS name="OTHER INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or of hypertensive crises.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>498-INDIRECT-SYMPATHOMIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG1>
<DRUG2>
<CLASS name="DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE" code="G02CB-001" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or of rapid elevation of blood pressure</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>498-INDIRECT-SYMPATHOMIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG1>
<DRUG2>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or of rapid elevation of blood pressure

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>498-INDIRECT-SYMPATHOMIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG1>
<DRUG2>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG2>
<DESCRIPTION>Perioperative hypertension</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In the case of scheduled surgery, it is preferable to stop the treatment several days before surgery.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>498-INDIRECT-SYMPATHOMIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Paroxystic hypertension, hyperthermia that can be fatal. Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI has been stopped</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>498-INDIRECT-SYMPATHOMIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG1>
<DRUG2>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or rapid elevation of blood pressure</DESCRIPTION>
<SEVERITY>Contraindication:</SEVERITY>
<COMMENT>with bupropion</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>498-INDIRECT-SYMPATHOMIMETICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="INDIRECT SYMPATHOMIMETICS" code="C01CA-R01BA" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA-SYMPATHOMIMETICS (ORAL AND/OR NASAL)" code="R01AA" /></DRUG2>
<DESCRIPTION>Risk of constriction of blood vessels and/or rapid elevation of blood pressure</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
